drugset / Trial / NCT07617740
IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)
Phase 0
Recruiting
18 enrolled
Peking University People's Hospital
Nanjing IASO Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, exploratory clinical study designed to evaluate the efficacy and safety of IASO207 Injection (in vivo CAR-T) in patients with active refractory systemic lupus erythematosus.
Timeline
- Start
- 2026-05-25
- Primary completion
- 2029-05-30
- Completion
- 2030-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IASO207 | Unknown | 5e+08 unknown | — |
| Subject | IASO207 | Unknown | 1e+09 unknown | — |
| Subject | IASO207 | Unknown | 2e+09 unknown | — |